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Implementation science is the study of
methods to promote the systematic
uptake of evidence based interventions
into practice and policy to improve
health. Despite the need for high
quality evidence from implementation
research, randomised trials of
implementation strategies often have
serious limitations. These limitations
include high risks of bias, limited use of
theory, a lack of standard terminology
to describe implementation strategies,
narrowly focused implementation
outcomes, and poor reporting. This
paper aims to improve the evidence
base in implementation science by
providing guidance on the
development, conduct, and reporting
of randomised trials of implementation
strategies. Established randomised trial
methods from seminal texts and recent
developments in implementation
science were consolidated by an
international group of researchers,
health policy makers, and practitioners.
This article provides guidance on the
key components of randomised trials
of implementation strategies, including
articulation of trial aims, trial

Summary points
Criticisms of current implementation trials include risks of bias, lack of theory
use, lack of standardised terminology to describe implementation strategies,
and limited measures and poor reporting
This article consolidates recent methodological developments in implementation
science with established guidance from seminal texts of randomised trial
methods to provide best practice guidance to improve the development and
conduct of randomised implementation trials
Consideration of such guidance will improve the quality and use of randomised
implementation trials for healthcare and public health improvement
the bmj | BMJ 2021;372:m3721 | doi: 10.1136/bmj.m3721

recruitment and retention strategies,
randomised design selection, use of
implementation science theory and
frameworks, measures, sample size
calculations, ethical review, and trial
reporting. It also focuses on topics
requiring special consideration or
adaptation for implementation trials.
We propose this guide as a resource for
researchers, healthcare and public
health policy makers or practitioners,
research funders, and journal editors
with the goal of advancing rigorous
conduct and reporting of randomised
trials of implementation strategies.
Investments in health research are not fully realised
because of delayed and variable uptake of effective
interventions by health systems and professionals.1-3
Implementation science seeks to resolve this problem
by generating evidence to facilitate the use and
integration of evidence based interventions into
health policy and practice.4 Just as well conducted
randomised clinical trials can provide robust estimates
of the effects of medical and surgical treatments,
well conducted randomised trials of implementation
strategies (which we refer to as implementation
trials) can provide robust assessments of the effects
of implementation strategies. These strategies include
audit and feedback, training, or reminders, on
measures of the uptake and integration of evidence
based interventions in healthcare and public health
practice.5
Although randomised trials are central to evidence
based medicine6 and are a common evaluation design
in the field of implementation science,7 concerns have
been raised about the quality of implementation trials.
Criticisms include high risks of bias, limited use of
theory, a lack of standardised terminology to describe
implementation strategies, limited measures, and poor
reporting.7-11 Progress in the field, however, has been
rapid with recent advances in implementation science
theory, concepts, terminology, measures, and reporting
standards to resolve many of these limitations.12-14
This article draws on recent developments in
implementation science with established randomised
1
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trial methods to provide a best practice guide to
improve the development, conduct, and reporting of
randomised implementation trials. This guidance was
authored by an international interdisciplinary group
with expertise spanning implementation science,
health services research, behavioural science, public
health, trial methods, biostatistics, and health policy
and practice. It discusses application of randomised
trial methods in the context of large scale trials of
implementation strategies, focusing on aspects that
might be unique to implementation studies. Table
1 defines key implementation terms used in the
guide.

Recommendations for the development, conduct, and
reporting of randomised implementation trials
When is an implementation trial warranted?
Implementation trials generate scientific knowledge
to improve the uptake of evidence based interventions
in practice. Researchers should consider several factors
when deciding whether a trial of implementation
strategies is needed,19 primarily the following:
•

•

•

A healthcare or public health intervention that is
supported by evidence as effective (ideally by a
systematic review of trials);
A known evidence-practice gap—that is, verifi
cation that the evidence based intervention is not
routinely implemented in practice;19 20 and
Equipoise regarding the effects of an implemen
tation strategy.

The need for a trial and the trial methods used
should also be guided by the needs, values, and
input of end users and other stakeholder groups.
A range of guidance documents are available to
identify appropriate groups to engage and undertake
meaningful research co-design across all phases of trial
design, conduct, and dissemination.21-23 Key features
of successful co-design include clearly articulated
roles and responsibilities in the process, research
training to end users, clear communication pathways,
and frequent interactions between researchers and
end users.24

Statement of the implementation trial aim
Randomised implementation trials should have
precisely stated aims, defining the population,
intervention, comparison, and outcome under
investigation. They should also distinguish clearly

between the aims of the implementation strategy
and the therapeutic intent of the targeted evidence
based intervention.12 For example: “The study
aimed to assess the effectiveness of audit and
feedback (implementation strategy), relative to
usual practice (implementation comparison) for
improving clinician (implementation population)
provision (implementation outcome, and target of
the implementation strategy) of nicotine replacement
therapy (clinical intervention) to inpatients of a cardiac
ward to support smoking cessation (therapeutic intent
of the clinical intervention).”
Randomised implementation trials can assess the
effect of a given strategy on implementation outcomes
alone, or assess both the effectiveness of the intervention
on clinical or population health therapeutic outcomes
as well as the effect of the implementation strategy on
implementation outcomes.25 Trials with a dual focus
are known as effectiveness-implementation hybrid
trials (table 2). Type I effectiveness-implementation
hybrid designs aim to evaluate the effects of an
evidence based intervention and describe or better
understand the context for implementation, but do
not test an implementation strategy.25 Type II and
III hybrid trials test implementation strategies on
implementation outcomes.25 Although hybrid designs
are suggested to be an efficient means of accumulating
evidence to inform implementation, the contribution
of type I and II trials to this end could be limited. This
limitation could be the case when research design
considerations to preserve the robust assessment
of clinical effectiveness questions are prioritised
over those considerations to assess the effect of
an implementation strategy (on implementation
outcomes).
As an example, a type II hybrid trial could express
dual aims as follows: “The primary aims of the
study were to: i) assess the effectiveness of audit
and feedback (implementation strategy), relative
to usual practice (implementation comparison) for
improving clinician (implementation population)
provision (implementation outcome, and target of
the implementation strategy) of nicotine replacement
therapy (clinical intervention); and ii) to assess
the effectiveness of nicotine replacement therapy
(clinical intervention), relative to usual care, in impro
ving smoking cessation (therapeutic outcome and
therapeutic intent of the clinical intervention) among
cardiac inpatients (therapeutic population).”

Table 1 | Definitions of key terms in implementation science
Term
Implementation science
Implementation strategy
De-implementation
Evidence based intervention
Implementation outcomes
Implementation trial
Clinical (therapeutic) trial

Adaptation

2

Definition
Scientific study of methods to promote the systematic uptake of evidence based interventions into practice and policy to improve health4
Method or technique used to enhance the adoption, implementation, and sustainability of an evidence based intervention15
Process of identifying and removing non-evidence based interventions that are harmful, not cost effective, or ineffective16
Evidence based practice, model of care, programme, policy, process, or guideline recommendation that is being implemented17
Process-of-care or quality measures (or related measures for public health) to assess the effects of the implementation strategy15 17
Research design testing the effects of implementation strategies on implementation outcomes5
Research that investigates the effect of a treatment or other intervention on patient health outcomes18
Degree to which an evidence based intervention is changed (eg, during intervention delivery) to suit the needs of the
setting or the target population17

doi: 10.1136/bmj.m3721 | BMJ 2021;372:m3721 | the bmj
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Table 2 | Typical characteristics of conventional clinical or public health trials, effectiveness-implementation hybrid trials, and implementation trials.
Adapted from Curran et al, 2012, with permission25
Conventional clinical
(therapeutic) or
public health trial
Research aim
To assess the
therapeutic effects of a
clinical or public health
intervention on
individual patient or
population health
outcomes

Effectiveness-implementation hybrid trials (type)
I

II

Primary: to assess the
Co-primary: to assess the therapeutic
therapeutic effectiveness of
effectiveness of a clinical or public health
a clinical or public health
intervention on individual patient or
intervention on individual
population health outcomes; and to assess
patient or population health
the effects of a strategy to implement a
outcomes; secondary: to
clinical or public health intervention on
describe or better understand
implementation outcomes
the context for implementation
Target of experimental manipulation (intervention or implementation strategy)
Individual patients, community Both individual patient’s community
Individual patients,
community members,
members, or populations
members, or populations; and clinicians,
policy makers, service providers or medical
or populations
or public health systems responsible for
implementation
Effects of therapeutic intervention on patient or population health outcomes of interest
Explicitly tested
Explicitly tested
Explicitly tested

Effects of implementation strategy on implementation outcomes
Typically not
Not tested
Explicitly tested
considered or required
as intervention delivery
is usually at the control
of, or administered by
researchers
Trial outcome measures
Clinical conditions,
Clinical conditions, patient
Both: clinical conditions, patient symptoms,
patient symptoms,
symptoms, health behaviours, health behaviours, disease risk factors,
health behaviours,
disease risk factors, or other
or other patient or population health
disease risk factors, or
patient or population health
related outcomes; professional practice
other patient or
related outcomes
improvement, changes in processes of care,
population health
adherence to clinical standards, quality of
related outcomes
intervention delivery or other
implementation outcomes

Recruitment and retention
Implementation trials usually recruit and randomise
staff or organisations rather than individual patients.
Intervention effects on clinical practice are often
assessed using routinely collected, anonymised data.
Therefore, implementation trials can be conducted at
relatively low cost, with potentially more complete trial
data than those from clinical trials that require intensive
recruitment and follow-up of patients.26 27 Nonetheless,
effective recruitment and retention approaches are
needed to ensure that all participant groups (patients,
clinicians, health services) are broadly representative
of the populations for which the findings are intended
to generalise. Minimising barriers to participation
is therefore critical to maximise external validity.
Consent procedures for participants to opt out could
be appropriate in some circumstances and can result
in high levels of participation,28 recruitment of more
typical participants groups, and more generalisable
effects.29-31 Opt out consent was recently used, for
example, in a randomised trial of mail-outs and phone
calls to improve adherence to secondary preventive
treatment after myocardial infarction that used
administrative data for outcome assessment.32
For research using active consent procedures,
recruitment and retention strategies recommended for
patients in clinical trials (such as dedicated recruitment
the bmj | BMJ 2021;372:m3721 | doi: 10.1136/bmj.m3721

III

Implementation trial

Primary: to assess the effects of a
strategy to implement a clinical or
public health intervention on
implementation outcomes; secondary:
to describe individual or population
therapeutic health outcomes associated
with implementation of an intervention

To assess the effects of a
strategy to implement a
clinical or public health
intervention on
implementation outcomes

Primary: clinicians, policy makers,
service providers or medical or public
health systems responsible for
implementation; secondary:
individual patients, community
members or populations

Clinicians, policy makers,
service providers or medical
or public health systems
responsible for
implementation

Not tested; known to be effective

Not tested; known to be
effective

Explicitly tested

Explicitly tested

Primary: professional practice
improvement, changes in processes of
care, adherence to clinical standards,
quality of intervention delivery or other
implementation outcomes; secondary:
health service use, clinical conditions,
patient symptoms, health behaviours, or
other health related outcomes

Professional practice
improvement, changes in
processes of care, adherence
to clinical standards, quality
of intervention delivery or
other implementation
outcomes

coordinators) and reminders for non-responders
also apply to the recruitment of patient groups in
implementation trials. Researchers can also leverage
the networks of relevant professional associations or
governing health authorities,33 34 engage potential trial
sites in the design of the study and its recruitment and
retention strategies to minimise the potential burden
of participation, ensure acceptability, and facilitate
the recruitment of health organisations and clinicians.
Because implementation trials aim to promote evi
dence based practice, they could be more attractive
to clinicians and organisations than other types of
research, particularly when stepped wedge or delayed
control group designs are used as all sites receive
implementation support as part of, or immediately
following, follow-up data collection.

Underlying trial philosophy: pragmatic and
explanatory trials
Explanatory trials use methods that prioritise internal
validity, and are undertaken in more ideal research
conditions.35 Pragmatic trials emphasise external
validity using methods more closely aligned to real
world contexts.35 Explanatory trials focus on questions
asking whether the intervention (or implementation
strategy) “can” work. Implementation trials are
inherently pragmatic because they usually focus on
3
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whether an intervention (or implementation strategy)
“does” work when delivered in routine clinical or
public health contexts.35 As such, the effect sizes of
interventions tested in pragmatic trials are typically
smaller than those reported in explanatory trials.36 37
The pragmatic explanatory continuum indicator
summary tool (PRECIS-2) describes the methodo
logical characteristics of explanatory and pragmatic
trials and can help researchers undertaking imple
mentation trials to make design decisions consistent
with the intended purpose and pragmatic nature
of implementation trials.38 The tool requires users
to consider trial eligibility criteria, recruitment
methods, setting, the expertise and resources required
for intervention implementation, the degree of
flexibility in the implementation and adherence to
the intervention, follow-up procedures, the selection
of relevant primary outcome measures, and analysis.
Furthermore, pragmatic trials might require departures
from conventional safety and integrity monitoring
processes, which have been largely designed for
explanatory studies. Simon et al offer some guidance
of adaptations that could be appropriate across
each of the key participant safety and trial integrity
obligations.39

Research trial design considerations
Non-randomised study designs are often used in
implementation research on the basis that they might
be more appropriate or feasible than a randomised
controlled trial. However, these designs could report
misleading estimates of effect even when experimental
groups appear similar on important prognostic factors,
and when such factors are considered in analyses.40
Randomised trials have also been suggested to be
unnecessary in instances when extreme effects are
anticipated, for example, when relative risks are less
than 0.25 or greater than 4.41 However such effect
sizes are rarely reported in implementation trials.
Because the process of random assignment of an
adequate number of units can effectively eliminate
the risk of confounding, randomised trials provide the
most robust evidence of the effects of implementation
strategies. Further, with improving access and
opportunity to use existing routinely collected data
such as registries and electronic medical records, such
designs are increasingly feasible.41 42
Nonetheless, randomised trials require inter
ventions that can feasibly be assigned at random.
Examination of the impact of national level legislative or regulatory changes on professional practice,
for example, are unlikely to be amenable to evalua
tion using randomised designs. Complex, adaptive
systems based strategies, and those developed
using complexity theory, have been tested as part
of randomised implementation trials,43 44 but there
are many challenges to doing so, particularly for
interventions in open systems without clearly defined
boundaries.45 Randomised trials of such strategies
may include mixed method research approaches,
in-depth case studies, and ethnographic narratives
4

to better understand system interconnectedness,
interactions, and impact.45 The development of
evaluation methods of these types of interventions
has been identified as a priority, and are beginning
to emerge.46 47
A variety of randomised trial designs can be used
in implementation trials (table 3). Researchers
undertaking implementation trials should be aware of
the relative merits of different randomised designs to
inform appropriate design selection.55 56 A thorough
description of randomised trial design limitations
(and strengths) is provided elsewhere and summarised
in supplementary file 1.55 57 Here, we discuss the
level of randomisation considerations, and describe
randomised trial designs that can be applied to assess
the effects of implementation strategies.

Level of randomisation

In an individually randomised trial, individual
participants (that is, patients)55 are randomised to
one of two or more parallel groups, and outcomes (eg,
clinical effectiveness) are measured at the same level
as the unit of randomisation (patient). Such trials
are relatively uncommon in implementation research
given that interventions often operate at multiple
levels and involve changes to health systems. Most
implementation trials using random assignment,
therefore, use cluster randomised designs (also called
group randomised designs).7 In these designs, clusters
such as hospitals or clinicians are randomised to receive
support to implement an evidence based interven
tion (an implementation strategy) or a comparison
condition, but where implementation outcome data
can be collected from multiple individuals (that is,
patients) within each cluster.55 Such outcome data
are usually correlated, and this clustering must be
accounted for in the design and analysis to obtain valid
statistical inferences.58
Many levels of clustering are possible in imple
mentation trials: for example, patients can be
clustered within clinicians, who could themselves be
clustered within a hospital, and hospitals could be
clustered within a healthcare organisation. The unit
of randomisation should be carefully chosen to reflect
the trial aims, and should consider trade-offs between
randomising at a higher level to prevent contamination
versus randomising at a lower level to increase
the number of units available for randomisation.
Contamination likely occurs even in cluster randomised
trial designs where individual clinicians within a
hospital are allocated to implementation training
and support, and then pass on such implementation
resources or knowledge to clinicians in the same
hospital allocated to a control condition. In such cases,
randomising at the level of the hospital or organisation
rather than the clinician can help mitigate this risk. On
the other hand, if the contamination is not substantial,
randomising at a lower level might be preferable, from
a statistical efficiency perspective.59 The higher the
level of randomisation, the fewer groups (eg, clinics,
hospital) may be available to be randomised.
doi: 10.1136/bmj.m3721 | BMJ 2021;372:m3721 | the bmj
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Table 3 | Description and key considerations of randomised designs for assessing the effects of implementation interventions
Description
Two arm, parallel randomised trial48
Individuals or groups (eg, clinics or schools)
consisting of multiple individuals
(eg, patients) are randomly assigned to
receive a treatment (implementation strategy)
or an alternative condition (eg, usual practice
or control)

Multi-arm randomised trial49
Investigate the effects of two or more
implementation strategies versus a
comparison (or alternative strategy) at the
same time. Such designs can involve
individual or cluster randomisation

Considerations

Example

Most appropriate when sample size or trial
resources are limited, and when there is an
interest in assessing the effect of one
implementation strategy compared with current
practice or an alternative implementation strategy

To evaluate the effectiveness of an implementation intervention to improve
six guideline recommended, health professional behaviours in managing
type 2 diabetes in primary care, 44 general practices were randomised to
implementation support or usual care control. Implementation support was
provided to clinicians within general practices allocated to receive it, while
the primary outcome included a patient survey of a random sample of
patients per practice that reported receipt of updated diabetes education
advice as well as routinely collected prescribing data for blood pressure,
insulin initiation for glycaemic control, and foot examinations from practice
records across practices26

Most appropriate when sample sizes are large,
when there is an interest in assessing the relative
effects of different implementation strategies
alone or in combination, and where there is
good control over the implementation strategies
provided to each group

To promote the uptake of evidence based guidance on blood transfusion in
surgery, a 2×2 factorial, cross sectional, cluster-randomised controlled trial
allocated NHS trusts* to receive one of the following: standard feedback
reports (usual care), standard reports with follow-on support, enhanced
reports, or enhanced reports with follow-on support. The primary outcome for
each topic will be the proportion of patients receiving a transfusion coded as
unnecessary using data from a national audit50

Stepped wedge randomised trials51
Following a baseline period, an
Most appropriate when a decision has been
implementation strategy is sequentially
made to roll out an implementation strategy
provided to clusters. The order in which the
across a health system, when risks of bias are
different clusters are assigned to receive the low, and when routinely collected data are
implementation strategy is randomised. Over available for outcome assessment
time, all units will have received
implementation support
Sequential trial design: sequential multiple assignment randomised trial53
Intervention dose, type, or delivery of an
Can be used to help many practical decisions
implementation strategy (or intervention) is
regarding how best to support improvements in
modified at several stages based on specified implementation. Most appropriate for the
decision rules. At each stage, the participant development of adaptive implementation
is randomly (re)assigned to one of several
strategies when a sufficient sample is available,
implementation strategy (intervention)
and where there is good control over the
options
implementation strategies provided to each
group

To improve the delivery of evidence based cardiovascular care in primary
care, practices were randomly assigned by region to receive implementation
support 12, 24, or 36 months after initiation of baseline data collection. The
primary outcome was mean adherence to indicators of evidence based care
as measured by chart review of a randomly selected cohort of 66 patients
per practice (measured before, during, and after receipt of implementation
support)52
To evaluate the effectiveness of a sequential approach to sustainment of a
postpartum depression prevention programme (EIAU) in outpatient clinics,
clinics at risk of not sustaining programme implementation will be randomised
to receive either no additional implementation support (that is, EIAU only),
or low intensity coaching and feedback (LICF). If clinics receiving LICF are still
at risk at subsequent assessments, they will be randomised to either LICF or
high intensity coaching and feedback. The primary outcome includes percent
sustainment of implementation of core programme elements54

*Trusts in the United Kingdom’s health service.

Parallel, two arm, randomised trial

Parallel, two arm, randomised implementation trials
compare the effects of an implementation strategy
with those of a control or alternative implementation
strategy. Conduct of two arm trials is useful when the
effects of one implementation strategy are primarily
of interest. These trials are more feasible than multiarm trials and are the most common randomised
design used to assess the effects of implementation
strategies.60 61

Multi-arm randomised trials

Multi-arm randomised trials provide information about
the comparative effects of multiple implementation
approaches. They represent a more efficient method
of testing the effects of implementation strategies
than performing sequential two arm trials.49 For
example, including three arms in a randomised
implementation trial could enable the comparison of
two implementation strategies with each other as well
as a comparison condition. In randomised factorial
designs, participants (or clusters) are randomised into
groups comprised of combinations of the experimental
conditions. Researchers interested in testing the
effects of implementation strategy A as well as those
of implementation strategy B within the same trial,
for example, might randomise participants into four
groups: A alone, B alone, both A and B, and neither A
the bmj | BMJ 2021;372:m3721 | doi: 10.1136/bmj.m3721

nor B.55 Such designs enable exploration of interactions
between groups, and the effects of implementation
strategies separately and in combination. Fractional
factorial randomised trials include larger numbers
of strategies, however, and allocate participants to
selected (rather than all) strategy combinations,
eliminating comparisons that are of no interest to
reduce the potential sample size requirements of the
trial.62 63
When an intervention must, for practical, logistical,
or organisational reasons, be rolled out to all units
in a health system, a stepped wedge design might be
useful. In stepped wedge randomised trials,57 64 all
units such as hospitals (clusters) are first recruited,
then randomised to receive the implementation
intervention at regular intervals (or steps) sequentially
over time, until all units have been exposed to the
intervention.65 66 Trial outcome data are collected at
regular intervals throughout the trial, with each unit
providing data for both experimental and control
conditions (periods). Under some circumstances, the
design might require fewer units to participate than
parallel arm, cluster randomised trials, particularly
when the intraclass correlation is high and cluster
period sizes are large. Stepped wedge trials require
repeated assessment of outcomes across the trial
periods, making these designs most suited for outcomes
that can be assessed using routinely collected data.
5
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Such designs are increasingly being used in health
services and implementation research, although they
are vulnerable to increased risks of bias and other
complexities that could make them less attractive than
parallel arm designs.64 65 67

Sequential trial designs

Sequential multiple assignment randomised trials
(SMART) are a type of adaptive design used to inform
the development of adaptive implementation strategies
(or interventions).53 68 In an adaptive implementation
strategy, the dose, type, or delivery of strategies is
modified across several stages based on prespecified
decision rules, providing individualised approaches
to better meet the specific needs and evolving status
of participants. With this design, participants are
randomised to different implementation strategy
options at each stage.68 For example, clinicians who
do not improve implementation of an intervention
following the provision of an initial package of
implementation strategies could receive different or
more intensive implementation support subsequently
than clinicians who do improve implementation.
The design allows researchers to assess the effect of
adaptive approaches and the isolation of the effects of
specific strategy modifications. Such designs involve
complex statistical considerations.

Hybrid trials

Hybrid trials can use any type of randomised trial
design. However, because they focus on assessing the
effects of implementation strategies on both clinical
effectiveness and implementation outcomes, design
modification might be needed (table 3).25 Design
modifications may often be required because clinical
effectiveness outcomes are usually assessed at an
individual level, while implementation outcomes
could be assessed at a provider or organisational level.
This duality of purpose of hybrid trialscan result in
research designs to assess outcomes at one level being
nested within a design determined by an outcome at
another level. For example, a randomised trial of the
introduction of a school nutrition policy might require
100 schools to participate to detect meaningful change
in school level policy implementation (implementation
outcome), but need only to assess students in a nested
random sample of 20 participating schools to identify
meaningful improvements in child dietary intake
(effectiveness outcome).

Reducing bias in randomised implementation trials
Researchers should be aware that randomised trials are
prone to threats to internal validity and seek to avoid
major risks of bias.56 As implementation trials often
include multiple outcomes assessed at different levels
(organisation, clinician, patient), research design
characteristics and risk of bias need consideration at
each level. For cluster trials, baseline comparability of
groups at both the cluster and individual levels can be
difficult to achieve if only a small number of clusters
such as hospitals are available for randomisation.69 70
6

In many cluster implementation trials, study sites
(clusters) such as clinics, might be randomised and
allocated before individual (that is, patient level)
recruitment. If those identifying and recruiting
participants (or the potential participants themselves)
are not blinded to allocation, differential recruitment
and study participation can occur (selection bias).71
Selection bias is a common problem in clustered
designs.72 In the UK BEAM trial, for example, primary
care practices were recruited and randomised.73
Clinicians at primary care practices allocated to the
experimental arm then received training in guideline
based management of back pain after which patient
recruitment commenced. In the study, practice nurses
recruited twice as many patients among primary care
practices allocated to receive training as those patients
allocated to usual care, and the characteristics of
patients differed between groups. Gatekeepers can also
withdraw their health site (cluster) from a trial once
informed of group allocation but before individual
participant level recruitment.71 Such circumstances
can be particularly challenging for intention-to-treat
approaches to analyses of trial outcomes, because little
is known about the characteristics of those individuals
who would have participated in that cluster.74
Selection bias can best be avoided by allocating units
after consent and baseline data collection.
In clinical trials, a lack of blinding of participants
and personnel delivering an intervention in a clinical
trial could increase the risk of bias,55 because
knowledge of assignment to an intervention might
lead to contamination, protocol deviations, or cointervention. However, the blinding of participants and
personnel is often inappropriate (and not possible) in
implementation trials because they seek to assess the
effect of an implementation strategy in individuals
or organisations aware of the care given. A range of
other strategies could reduce the risks of such biases
including the use of clustered designs,75 simply asking
clinicians or patients not to share information, trial
intervention or implementation strategy sessions that
are spatially or temporally separate, and systems to
avoid transfer of patients between clinicians.76 The
effectiveness of these strategies, however, is unclear. If
adequately assessed, statistical approaches can also be
used to adjust for contamination in analyses.77-79 The
Cochrane risk-of-bias tool (version 2)56 for randomised
trials provides a comprehensive description of
potential risks of bias for various randomised designs
and strategies to help identify and reduce such risks.

Models, theories, and frameworks
The lack of explicit descriptions of the mechanism by
which implementation strategies are hypothesised
to exert their effects is suggested to reduce the ability
to judge the generalisability of trial findings across
settings and contexts, to limit understanding of
implementation processes and to slow the cumulative
progression of the field.80-83 As such, implementation
trials should include an explicit programme theory,81 or
a logic model that details the rationale and assumptions
doi: 10.1136/bmj.m3721 | BMJ 2021;372:m3721 | the bmj
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Table 4 | Description of models, theories, and frameworks used in implementation strategy design. Adapted from Nilsen, 201585
Theory or framework type
Classic theories (eg, theory of planned
behaviour, social cognitive theory, situated
change theory)86-88
Implementation theories (eg, implementation
climate, organisational readiness to change,
normalisation process theory)89-91

Determinants frameworks (eg, consolidated
framework for implementation research,
theoretical domains framework)14 92

Description
Originate from related disciplines (eg, psychology) and help
understand or explain individual, group, or organisational
behaviour. They describe precise mechanisms of behaviour change
Theories developed (or adapted classical theories) specifically to
understand, explain, and inform implementation. They describe
precise mechanisms of change for one or more aspect of
implementation
Often developed through the consolidation of constructs from of
a range of theories, they aim to understand and explain factors that
could influence (facilitate or impede) implementation. They typically
do not describe mechanisms for change

about the mechanisms linking implementation
strategy (and intervention),84 processes, and inputs to
trial outcomes. A programme theory can be developed
using informal theory—that is, understanding of
the problem and its determinants gained through
experience or tacit knowledge by the developers of the
intervention. However, we recommend that the use of
informal theory is coupled with the formal behavioural
or implementation theories or frameworks (table 4).85
Although a range of theories and frameworks exist, few
are supported empirically,93 and some are known to be
of little use in predicting or explaining behaviour.94
Determinant frameworks can be particularly useful
in implementation strategy development because
they consolidate several behavioural theories and
identify a comprehensive range of multilevel factors
that are theoretically (or empirically) linked with
implementation outcomes. In addition to the extent to
which a theory or framework is empirically supported,
criteria including usability, testability, familiarity, and
applicability should be considered when comparing
and selecting a model, theory, or framework.95
Several useful resources are available to support
the application of formal theory in the development of
broader programme models and specific implementation
strategies.96 French et al propose a four step process
for such a development (table 5).97 Other systematic
methods for developing implementation strategies also
exist,99 100 which typically involve four common steps:
barrier identification, linking barriers to implementation
strategy component selection, use of theory, and
user engagement.99 Importantly, the development of
programme theory and implementation strategies
requires a thorough understanding of the problem, its
determinants, and context in which implementation
needs to occur and so should involve considerable end
user engagement and formative evaluation.100

Application
Classic and implementation theories describe precise
mechanisms of behaviour and behaviour change. One or
more of these theories can be used to developed targeted
implementation strategies and describe how change in the
behaviour of those involved in an implementation process
is anticipated to occur

Determinants frameworks can help identify factors thought
to be associated with implementation, and implementation
strategies that can be used to address these, from which
programme theory can be developed

Measures
Trial outcome measures
The selection of outcome measures should be linked
directly to trial primary and secondary aims and enable
the robust quantification of an effect. Proctor and
colleagues proposed a taxonomy of eight conceptually
distinct implementation outcomes, namely accepta
bility, adoption, appropriateness, feasibility, fidelity,
implementation cost, penetration, and sustaina
bility.101 From a trial design perspective, the collective
labelling of such measures as “outcomes,” is a
misnomer that has created some confusion,102 because
many of these measures do not lend themselves to the
reporting of an effect size. For example, measures of
the acceptability of an intervention (or implementation
strategy) can only be reported in the trial group in
receiving it, precluding between group comparisons.
Many of these measures might be better aligned to the
assessment of implementation processes and other
factors influencing implementation.42 102
Most implementation trials primarily focus on
measuring the extent to which an implementation
strategy achieved implementation of the targeted
evidence based intervention (eg, a guideline) such
as measures of professional practice improvement,
changes in processes of care, adherence to clinical
standards, or the amount or quality of programme or
intervention delivery.7 As measures of such outcomes
are often unique to the intervention being implemented
and its context, generic standard measures are
unlikely to be available. Instead, researchers might
identify or develop measures that assesses their
specific implementation outcome and context, for
example, using data collected as part of environmental
observations, routinely collected administrative
records, or questionnaires. The limitations of each
of these approaches need to be considered,103 but as

Table 5 | Suggested steps for the development of a theory informed implementation strategy. Adapted from French et al, 201297
Steps
1
2

3
4

Description
Identify who (eg, individuals or professional groups) needs to do what differently in order for implementation to be improved98
Using informal and formal theory and frameworks, identify barriers and enablers that need to be resolved, and articulate a pathway of change for the targeted
behaviour change to occur. A variety of research methods, including literature reviews and local qualitative and quantitative data collection, should be used to
support the development of the change pathway (programme theory)
Select implementation strategies (behaviour change techniques, modes of delivery) that might be effective, locally relevant, acceptable, and feasible to overcome
identified barriers and enhance facilitators to change. Selection of strategies could be based on matrices recommended by determinant frameworks, empirical
evidence, and engagement with end users
Decide how change in implementation can be robustly and feasibly measured, including factors on the hypothesised casual pathway (mediators) and appropriate
implementation outcomes
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Table 6 | Implementation measures used to establish and support evidence based interventions. Adapted from Proctor et al, 2011, with permission101
Measures

Acceptability
Adoption
Appropriateness
Feasibility
Fidelity
Cost
(incremental or implementation cost)
Penetration
Sustainability

Description
Perception among implementation stakeholders that an evidence based intervention (or implementation strategy) is agreeable,
palatable, or satisfactory
Intention, initial decision, or action to try or use an evidence based intervention (or implementation strategy). Adoption also can be
referred to as “uptake”
Perceived fit, relevance, or compatibility of an evidence based intervention (or implementation strategy) for a given practice setting,
provider, or consumer; or perceived fit of the innovation to resolve a particular issue or problem
Extent to which an evidence based intervention (or implementation strategy) can be successfully used or carried out
Degree to which an evidence based intervention (or implementation strategy) was delivered as it was intended

Cost or relative cost of the implementation of an evidence based intervention
Integration of an evidence based intervention within a service setting and its subsystems
Extent to which a newly implemented evidence based intervention is maintained or institutionalised within a
service setting’s ongoing, stable operations

trial outcomes, such measures should be robust, and
sensitive to change. Multiple outcome measures should
also be used in trials to provide a more comprehensive
appraisal of the effects of an implementation strategy,
acknowledging how these measures are related to
each other and the inherent limitations of single
measures of implementation.42 103 For trials focused
on assessment of individual patient level outcomes,
clinical outcomes should be sufficiently proximal and
arise exclusively (or mostly) from the improvements
in clinical practice targeted by the implementation
strategy.104 For example, in a study to improve survival
from heart attack, researchers noted that even if perfect
compliance with care standards in a hospital could be
achieved, the anticipated changes in cardiac mortality
(or survival) would be insufficient to feasibly detect in
a trial.105

Process evaluation

Process evaluation provides important depth to the
interpretation of trial outcomes. Qualitative and
mixed method approaches can elucidate insights
to better understand how and why implementation
might improve (or not) following the application
of an implementation strategy, and key contextual
factors that might influence it. Several publications,
including a white paper by the Qualitative Research
in Implementation Science (QualRIS) group (an expert
group convened by the National Institute of Health),
provide guidance for the use of qualitative methods
in implementation science, including discussion of
design, data collection, and analytical methods as well
as recent developments in the field.106 107 While several
approaches have been suggested to undertake process
evaluations,108-111 here we offer guidance consistent
with the United Kingdom’s Medical Research Council,
which suggests process evaluations include assessment
of implementation processes, mechanism of impact,
and contextual factors that shape outcomes.112

Implementation processes

Implementation processes are specific policies,
practices, and strategies that are used to establish
and support an intervention.101Table 6 provides
a range of measures proposed by Proctor et al101
that might be useful for exploring implementation
8

processes. Such measures, for example, could be
used to describe characteristics of the evidence based
intervention, or the implementation strategy (table 6).
The psychometric properties of a range of existing tools
that assess these have recently been reported.113 114
Additionally, because evidence based interventions are
often adapted by end users (such as clinicians) in the
process of their implementation, the documentation,
recording, and reporting of adaptations has been
suggested to be important to understanding the effects
of efforts to implement evidence based interventions.12
A framework by Stirman et al provides more detailed
guidance of how to do so.115 The use of qualitative
inquiry has also been recommended by QualRIS to
assess adaptation and other implementation processes
while ethnography has been suggested to be well
suited to assess implementation microprocesses at the
level of individual interactions.107

Implementation mechanisms

The mechanism by which an implementation
strategy exerts its effects is important to understand
in order to identify how these effects might be
replicated and improved.112 To develop such an
understanding, specific analytical methods can be
applied to assess casual assumptions of the pathways
specified by the programme theory.116-119 Such
mechanistic evaluations require clear specification
of implementation strategies, links between strategy
and mechanism, identification of outcomes, and (if
relevant) articulation of effect modifiers.119 Some
classic theories, implementation theories, and determinants frameworks have existing measures of
factors theoretically linked to implementation out
comes. Several reviews of such measures have been
published,120 of which the most comprehensive is the
Instrument Review Project, funded by the National
Institutes of Health.13 Reviews, however, suggest that
implementation mechanisms are rarely tested in trials
of implementation strategies,121 122 and where testing
has occurred, often it is undertaken inappropriately. To
best understand the multilevel and interdependence
of factors that might influence implementation,
sophisticated quantitative and qualitative methods
are required.123 124 Lewis and colleagues suggest
that common quantitative approaches to mediation
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testing in implementation trials are suboptimal, and
that the product of coefficients approach might be
preferable given its capacity to examine single level
and multilevel mediation and maximise power.122
Further, qualitative approaches have been suggested
to be particularly useful in the absence of established
quantitative measures, and structured qualitative
inquiry can help deepen an understanding of
mechanistic processes.107 122 Contemporary guidance
on mechanistic evaluation, including how it is applied
in implementation science, is provided in more detail
elsewhere.122

Implementation contexts

Context refers to external factors that might act as a
barrier or facilitator to implementation, or influence
the effects of an implementation strategy.12 112
Descriptions of context, therefore, provide critical
information regarding the external validity of trial
findings and enable readers to assess the applicability
of the findings to their own setting. Context measures
can include measures of the social, political, or
economic environment that might influence imple
mentation.12 These measures include leadership,
workforce capacity, readiness to change, and other
organisational or patient characteristics.125 Some
randomised implementation trials have also used
systematic reviews of news archives, and of websites
of relevant agencies to assess changes in government
policy, guidelines, accreditation standards or funded
programmes that might influence implementation
or confound trial outcomes.126 127 Quantitative or
qualitative measures of context can also be assessed
analytically to examine their potential role in shaping
implementation processes or outcomes in the context
of the broader programme theory.42

Sample size calculation
Sample size calculations estimate the number of
participants required to detect the hypothesised
effect of an implementation strategy with acceptable
power.128 129 While sample size calculations for
clinical effectiveness trials are based on treatment
effects identified as of sufficient magnitude to provide
a clinical therapeutic benefit to a patient,129 sample
size calculations for implementation trials need to
consider a meaningful or worthwhile effect size for an
implementation outcome from a population or system
level perspective. Because implementation strate
gies typically seek to improve the implementation
of existing evidence based interventions of known
therapeutic benefit, any improvement in imple
mentation may increase the number of patients or
the community exposed to (and benefiting from)
evidence based healthcare. Strategies that lead to
small improvements in implementation might be
meaningful from a system perspective if they can
be delivered, easily, at low cost, and at a population
level. Sample size calculations need to use parameters
required for the type of randomised design undertaken
and researchers should follow design specific advice
the bmj | BMJ 2021;372:m3721 | doi: 10.1136/bmj.m3721

to do so.130 Because implementation trials can have
participants at multiple levels, sample size calculations
are usually more complicated than those for clinical
effectiveness trials, and might need to consider the
relative contributions to the power of increasing the
numbers of participants at each level.

Research ethics review
As implementation trials meet the definition of
research (a systematic investigation designed to
produce generalisable knowledge) and involve human
research participants (which could include health
professionals),131 ethical review by an institutional
review board is required before trial commencement.
Implementation trials can occur in the context of usual
service improvement activities that can complicate
the nature of consent for research participation.132 133
Implementation trials often involve participants at
multiple levels, so research ethics review is more
complicated. Although no specific ethical statements
exist pertaining to implementation trials,133 the
Ottawa Statement on the Ethical Design and Conduct of
Cluster Randomised Trials covers such issues, and has
recently been applied to trials of knowledge translation
interventions.134 135 The statement provides guidance
to help identify research participants (patients,
clinicians, and managers), and lists requirements for
organisational governance, assessing benefits and
harms, and protecting vulnerable participants (table
7). A key consideration when submitting a protocol
to a research ethics committee is identifying the
human research participants in the trial.136 Research
participants can be identified as any individual
whose interests might be affected as a result of study
interventions or data collection procedures.136 In
some implementation trials, patients might not be
considered research participants (that is, they do not
have any study interventions directed at them, or
do not have their identifiable data collected for the
purposes of research). When patients are not research
participants, their informed consent is not required.137
However, when employees such as clinicians are the
recipients of an implementation strategy, and are
involved in data collection or where identifiable data
are collected about them, their consent is required.
Approval might also be required from gatekeepers
such as an organisational leader for such research to
be undertaken in their facility.
Reporting
The Standards for Reporting Implementation Studies
(StARI) guide has been designed specifically to
facilitate the better reporting of implementation trials
and should be used in conjunction with the CONSORT
reporting guideline (and extension) specific to the
type of randomised trial design used.12 Efforts to test
the effectiveness of implementation strategies have
been hindered by a lack of conceptual clarity owing
to inconsistent definitions and insufficient detail to
enable replication.9 To resolve this, StaRI recommend
the use of the Template for Intervention Description
9
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Table 7 | Selected ethical issues included in the Ottawa Statement on the Ethical Design and Conduct of Cluster Randomised Trials that are relevant to
implementation trials. Adapted from Taljaard et al, 2013134
Ethical issue
Identifying research
participants

Informed consent
Organisational
governance approval
Assessing benefits
and harms
Protecting vulnerable
participants

Summary of recommendation
Research participants are any individuals who are the intended recipients of an implementation strategy (or control) or are the target of an
experimental manipulation of their environment; investigators interact for the purpose of collecting data about that individual; or who provide
personal data for research purposes. Participants could include clinicians, health service, or other staff, where implementation initiatives are occurring
Informed consent is required from all individuals who meet the criteria for research participants before data collection or intervention exposure unless
a waiver is granted from an ethics review board. Waiver or alternate consent procedures may be granted when the research poses no more than
minimal risk and the study is not feasible without the alteration of consent
Where research might substantially affect organisations (or other cluster unit) interests, permission to undertake it should be sought from
stakeholders who have legitimate authority to make decisions on behalf of the organisation. When research might substantially affect cluster
interests, researchers should seek to protect cluster interests through cluster consultation with organisations (eg, gatekeepers) to inform study design
conduct and reporting. Such organisational stakeholders may not provide consent on behalf of research participants
Researchers must justify the intervention and data collection procedures, as well as the selection of the control condition. The research should not
deny access to effective care or programmes to which would otherwise be accessible to patients or providers of care. Benefits and harms of
participation must be considered, and stand in reasonable relation to anticipated knowledge gain
Additional protection might be needed for research, including vulnerable participant groups (eg, those unable to provide informed consent, at
particular risk of harm, or in subordinate organisational or social positions)

and Replication (TIDieR) checklist when describing
the evidence base intervention that is subject to
implementation.12 138 Similar recommendations have
been proposed for standardising description of
implementation strategies,15 and implementation
researchers should describe implementation strategies
using an established taxonomy (eg, the Behaviour
Change Technique or Expert Recommendations for
Implementation Change taxonomies).9 15 139 140 The
identification of core and non-core components of
the implementation strategy, based on the underlying
programme theory, should also be articulated.

Conclusion
High quality randomised trials have a key role in
advancing implementation science by providing robust
evidence on the effects of approaches to improve the
uptake and integration of evidence based practice. With
the emergence of more accepted concepts, terminology,
processes, and reporting standards in the field, the
opportunity to improve the development, conduct, and
reporting of such trials is considerable.12-14 This article
summarises the latest guidance on the best practice
randomised trial and implementation science methods
to fulfil this need for improvement. The development
of guidance documents have proved a useful resource
in improving the rigour of randomised controlled trials
in healthcare and public health.141 This guide is also
aimed at journal editors, reviewers, and funders of
implementation research as a resource to improve the
quality of the implementation science evidence base.
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